Drugs & Targets FDA accepts sNDA for Lonsurf for metastatic gastric/gastroesophageal junction adenocarcinoma; grants Priority Review October 26, 2018Vol.44 No.40
Drugs & Targets BMS provides update on regulatory review of Opdivo + Yervoy in first-line lung cancer October 26, 2018Vol.44 No.40
Drugs & Targets Zai Lab announces approval of Zejula in relapsed ovarian cancer in Hong Kong October 26, 2018Vol.44 No.40
Drugs & Targets NCCN awarded $2M to study Taiho’s Trifluridine and Tipiracil in various cancers October 26, 2018Vol.44 No.40
Drugs & Targets Myriad’s test receives FDA approval as companion diagnostic for Pfizer’s Talzenna October 19, 2018Vol.44 No.39
Drugs & Targets Huge variations between countries in time for reimbursement decisions on new cancer drugs October 19, 2018Vol.44 No.39
Drugs & Targets AbbVie’s sNDA accepted for priority review for Imbruvica in combination with Gazyva for previously untreated CLL October 19, 2018Vol.44 No.39
Drugs & Targets The Parker Institute, Xyphos Biosciences developing universal programmable CAR-T cells October 19, 2018Vol.44 No.39
Drugs & Targets PanTher Therapeutics, MD Anderson collaborate on pancreatic cancer treatment October 19, 2018Vol.44 No.39
